サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1756412

疼痛管理治療薬の世界市場：疼痛の種類別・薬剤クラス別・投与経路別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Pain Management Therapeutics Market, By Type of Pain, By Drug Class, By Administration Route, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 398 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
疼痛管理治療薬の世界市場：疼痛の種類別・薬剤クラス別・投与経路別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年05月23日
発行: AnalystView Market Insights
ページ情報: 英文 398 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

疼痛管理治療薬の市場規模は2024年に849億7,800万米ドルとなり、2025年から2032年にかけてCAGR 3.78％で拡大しました。

この市場を牽引する要因としては、慢性疾患の有病率の上昇、人口の高齢化、疼痛管理の選択肢に対する意識の高まりなどが挙げられます。また、薬剤の製剤・送達方法の革新も治療の可能性を広げています。さらに、非中毒性でより安全な代替鎮痛剤に対する需要の高まりが市場動向を形成しています。この分野は、がん、関節炎、神経障害性疾患、術後の回復に関連する痛みを対象としています。全体として、世界中で経験される最も一般的で課題となっている症状の1つに対処することで、医療において重要な役割を果たしています。

疼痛管理治療薬の市場力学

非オピオイド系鎮痛薬に対する需要の高まりが、より安全な代替療法を促進

非オピオイド鎮痛薬に対する需要の高まりは、疼痛管理治療薬市場の重要な促進要因です。オピオイドの中毒、乱用、副作用に対する懸念が、患者と医療提供者の双方に、より安全な代替療法を求めるよう促しています。非ステロイド性抗炎症薬（NSAID）、抗けいれん薬、抗うつ薬、局所治療薬などの非オピオイド治療薬は、より低いリスクプロファイルで効果的な疼痛緩和を提供します。

この変化は、世界の意識向上キャンペーンやオピオイド処方に対する規制強化によって支えられています。さらに、研究の進歩により、疼痛メカニズムをより正確に標的とする革新的な非オピオイド薬が生み出されつつあります。その結果、市場はこうしたより安全な選択肢を含むポートフォリオを拡大しつつあります。この動向は、オピオイドの長期使用がしばしば問題となる慢性疼痛疾患の管理において特に重要です。全体として、非オピオイド療法への需要が治療アプローチを再構築し、市場の成長を加速させています。

疼痛管理治療薬市場：主な考察

弊社リサーチアナリストの分析によると、世界市場は予測期間（2025-2032年）に約3.78%のCAGRで年間成長すると推定されます。

痛みのタイプ別セグメンテーションでは、慢性痛が2024年に最大市場シェアを示すと予測されます。

薬剤クラス別では、オピオイドが2024年の主要薬剤クラスです。

投与経路別では、経口剤が2024年に市場をリードします。

エンドユーザーセグメンテーションでは、2024年に病院が主要市場となっています。

地域別では、北米が2024年の売上高でトップ

疼痛管理治療薬市場：セグメンテーション分析

疼痛管理治療薬の世界市場は、疼痛の種類、薬剤クラス別、流通、エンドユーザー、地域に基づいてセグメント化されます。

疼痛タイプ別では、急性疼痛、慢性疼痛、がん性疼痛、神経障害性疼痛、術後疼痛の5つに分類されます。慢性疼痛は、広く蔓延し、長期間持続する性質があるため、疼痛管理治療薬市場において支配的なセグメントです。怪我や手術に関連した一時的な急性疼痛とは異なり、慢性疼痛は数カ月から数年にわたり持続し、多くの場合、関節炎、神経障害、線維筋痛症などの疾患に起因します。慢性疼痛は患者のQOLや日常生活に大きな影響を与えるため、その管理は非常に難しいです。このため、効果的で持続可能な疼痛緩和療法に対する需要が高まっています。世界の高齢化と慢性疾患の増加は、慢性疼痛をターゲットとした革新的な治療法の必要性をさらに高めています。

市場は薬剤クラス別に5つのカテゴリーに分類されています。オピオイド、非オピオイド鎮痛薬、補助鎮痛薬、局所鎮痛薬、その他です。オピオイドは、中等度から重度の疼痛を緩和する強い有効性により、疼痛管理治療薬市場において依然として支配的な薬剤クラス別です。オピオイドは脳や脊髄のオピオイド受容体に結合することで作用し、痛みの知覚を著しく低下させる。その高い有効性にもかかわらず、中毒や副作用の懸念から規制が強化され、慎重な使用が求められています。しかし、オピオイドは、特にがん性疼痛や術後の疼痛管理に広く処方され続けています。より安全なオピオイド製剤の開発が進められているのは、痛みの緩和とリスクの最小化のバランスをとるためであり、疼痛治療薬におけるオピオイドの重要な役割は維持されています。

疼痛管理治療薬市場：地域別分析

北米地域は、医療インフラが整備されており、慢性疼痛疾患の有病率が高いことから、疼痛管理治療薬市場で優位な地位を占めています。米国は、高齢化に伴う関節炎、がん、神経障害性疼痛の増加により、市場をリードしています。さらに、疼痛管理の選択肢に対する意識の高まりと先進的な治療法の普及が市場成長に寄与しています。同地域の規制当局はより安全な疼痛管理を推進しており、これが非オピオイド代替薬へのシフトを加速させています。

米国は北米の疼痛管理治療薬市場において最大の貢献国であり、慢性疼痛疾患の高い有病率と高齢化がその要因となっています。オピオイド中毒に対する意識の高まりが、より安全な非オピオイド鎮痛オプションへの需要を後押ししています。強固な医療インフラ、先進的な調査、疼痛管理を支援する政府の取り組みが、市場の成長をさらに後押ししています。主要製薬企業の存在も、疼痛治療薬の継続的な技術革新を促進しています。

疼痛管理治療薬市場：競合情勢

疼痛管理治療薬市場の競合情勢は非常にダイナミックで、主要製薬企業やバイオテクノロジー企業間の激しい敵対関係が特徴です。主要企業は、市場での地位を強化するために、製品の革新、戦略的提携、買収に注力しています。各社は、規制要件や患者の嗜好の変化に対応するため、より安全で効果的な疼痛緩和薬、特に非オピオイド療法を開発するための研究開発に多額の投資を行っています。

市場はまた、製剤、デリバリー技術、価格戦略に基づく競争にも立ち会っています。斬新な治療ソリューションを持つ新興企業が既存企業に課題し、さらなる技術革新を促しています。さらに、企業は提携やライセンシング契約を通じて地理的プレゼンスを拡大しています。オピオイド危機の進行により、各社は代替疼痛管理療法の開発を加速させており、市場競争は激化しています。全体として、このような競合環境は、世界中の患者と医療提供者に利益をもたらす絶え間ない進歩を促進しています。

目次

第1章 疼痛管理治療薬市場の概要

  • 分析範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 疼痛管理治療薬の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 疼痛管理治療薬市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 疼痛管理治療薬市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 疼痛管理治療薬の市場情勢

  • 疼痛管理治療薬の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 疼痛管理治療薬市場：疼痛の種類別

  • 概要
    • セグメント別シェア分析：疼痛の種類別
    • 急性疼痛
    • 慢性疼痛
    • がんの痛み
    • 神経障害性疼痛
    • 術後の痛み

第8章 疼痛管理治療薬市場：薬剤クラス別

  • 概要
    • セグメント別シェア分析：薬剤クラス別
    • オピオイド
    • 非オピオイド鎮痛剤
    • 補助鎮痛剤
    • 局所鎮痛剤
    • その他

第9章 疼痛管理治療薬市場：投与経路別

  • 概要
    • セグメント別シェア分析：投与経路別
    • 経口剤
    • 注射剤
    • 経皮
    • 局所

第10章 疼痛管理治療薬市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 病院
    • 外来手術センター
    • 在宅医療
    • その他

第11章 疼痛管理治療薬市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ（MEA）
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析：疼痛管理治療薬業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Johnson &Johnson
    • Pfizer Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Novartis AG
    • Grunenthal GmbH
    • Mylan NV
    • Mallinckrodt Pharmaceuticals
    • Sanofi SA
    • Allergan（AbbVie）
    • AstraZeneca plc
    • Endo International plc
    • Bristol-Myers Squibb
    • Bayer AG
    • AcelRx Pharmaceuticals

第13章 AnalystViewの全方位的分析

目次
Product Code: ANV5318

REPORT HIGHLIGHT

Pain Management Therapeutics Market size was valued at US$ 84,978 Million in 2024, expanding at a CAGR of 3.78% from 2025 to 2032.

The Pain Management Therapeutics Market focuses on treatments and medications designed to relieve or reduce pain caused by various medical conditions. This market includes a wide range of products such as opioids, non-opioid analgesics, anti-inflammatory drugs, topical agents, and advanced therapies like nerve blocks and neuromodulation. The primary goal is to improve patient quality of life by managing acute and chronic pain effectively.

Factors driving this market include the rising prevalence of chronic diseases, an aging population, and increasing awareness about pain management options. Innovations in drug formulations and delivery methods are also expanding therapeutic possibilities. Additionally, the growing demand for non-addictive and safer pain relief alternatives is shaping market trends. The sector covers pain related to cancer, arthritis, neuropathic conditions, and postoperative recovery. Overall, it plays a critical role in healthcare by addressing one of the most common and challenging symptoms experienced worldwide.

Pain Management Therapeutics Market- Market Dynamics

Rising demand for non-opioid pain relief fuels safer therapeutic alternatives.

The rising demand for non-opioid pain relief is a significant driver in the Pain Management Therapeutics Market. Concerns over opioid addiction, abuse, and side effects have pushed both patients and healthcare providers to seek safer alternatives. Non-opioid therapies, including NSAIDs, anticonvulsants, antidepressants, and topical treatments, offer effective pain relief with lower risk profiles.

This shift is supported by growing awareness campaigns and stricter regulations on opioid prescriptions worldwide. Additionally, advancements in research are producing innovative non-opioid drugs that target pain mechanisms more precisely. As a result, the market is expanding its portfolio to include these safer options. This trend is especially important in managing chronic pain conditions, where long-term opioid use is often problematic. Overall, the demand for non-opioid therapies is reshaping treatment approaches and accelerating market growth.

Pain Management Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.78% over the forecast period (2025-2032)

Based on Type of Pain segmentation, Chronic Pain was predicted to show maximum market share in the year 2024

Based on Drug Class segmentation, Opioids was the leading Drug Class in 2024

Based on Administration Route segmentation, Oral was the leading distribution in 2024

Based on end-user segmentation, Hospitals was the leading distribution in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pain Management Therapeutics Market- Segmentation Analysis:

The Global Pain Management Therapeutics Market is segmented on the basis of Type of Pain, Drug Class, Distribution, End-user, and Region.

The market is divided into five categories based on Type of Pain: Acute Pain, Chronic Pain, Cancer Pain, Neuropathic Pain, Postoperative Pain. Chronic pain is the dominant segment in the Pain Management Therapeutics Market due to its widespread prevalence and long-lasting nature. Unlike acute pain, which is temporary and linked to injury or surgery, chronic pain persists for months or years, often resulting from conditions like arthritis, neuropathy, or fibromyalgia. Managing chronic pain is challenging because it significantly affects patients' quality of life and daily functioning. This has led to a growing demand for effective and sustainable pain relief therapies. The rising number of aging populations and chronic disease cases worldwide further drive the need for innovative treatments targeting chronic pain.

The market is divided into five categories based on Drug Class: Opioids, Non-Opioid Analgesics, Adjuvant Analgesics, Topical Analgesics, Others. Opioids remain the dominant drug class in the Pain Management Therapeutics Market due to their strong effectiveness in relieving moderate to severe pain. They work by binding to opioid receptors in the brain and spinal cord, significantly reducing pain perception. Despite their high efficacy, concerns over addiction and side effects have led to increased regulation and cautious use. However, opioids continue to be widely prescribed, especially for cancer pain and postoperative pain management. The ongoing development of safer opioid formulations aims to balance pain relief with minimizing risks, maintaining their key role in pain therapeutics.

Pain Management Therapeutics Market- Geographical Insights

The North American region holds a dominant position in the Pain Management Therapeutics Market due to its well-established healthcare infrastructure and high prevalence of chronic pain conditions. The United States leads the market, driven by increasing cases of arthritis, cancer, and neuropathic pain among its aging population. Additionally, growing awareness about pain management options and widespread adoption of advanced therapies contribute to market growth. Regulatory agencies in the region are promoting safer pain management practices, which has accelerated the shift toward non-opioid alternatives.

The United States is the largest contributor to the Pain Management Therapeutics Market within North America, driven by a high prevalence of chronic pain conditions and an aging population. Increased awareness about opioid addiction has boosted demand for safer, non-opioid pain relief options. Robust healthcare infrastructure, advanced research, and government initiatives supporting pain management further strengthen market growth. The presence of leading pharmaceutical companies also fosters continuous innovation in pain therapeutics.

Pain Management Therapeutics Market- Competitive Landscape:

The competitive landscape of the Pain Management Therapeutics Market is highly dynamic and characterized by intense rivalry among leading pharmaceutical and biotech companies. Key players focus on product innovation, strategic partnerships, and acquisitions to strengthen their market positions. Companies are investing heavily in research and development to create safer and more effective pain relief options, particularly non-opioid therapies, to meet changing regulatory requirements and patient preferences.

The market also witnesses competition based on drug formulations, delivery technologies, and pricing strategies. Emerging players with novel therapeutic solutions are challenging established firms, driving further innovation. Additionally, companies are expanding their geographic presence through collaborations and licensing agreements. The ongoing opioid crisis has pushed companies to accelerate development of alternative pain management therapies, increasing market competition. Overall, this competitive environment fosters continuous advancements that benefit patients and healthcare providers worldwide.

Recent Developments:

In January 2025, Vertex Pharmaceuticals received FDA approval for Journavx (suzetrigine), a novel non-opioid painkiller for moderate-to-severe acute pain. This marks the first approval of a new class of pain medication in over two decades. Journavx targets sodium channels specific to pain neurons, offering effective pain relief without the addictive potential of opioids. The approval signifies a significant advancement in non-opioid pain management options.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Johnson & Johnson
  • Pfizer Inc.
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • Grunenthal GmbH
  • Mylan N.V.
  • Mallinckrodt Pharmaceuticals
  • Sanofi S.A.
  • Allergan (AbbVie)
  • AstraZeneca plc
  • Endo International plc
  • Bristol-Myers Squibb
  • Bayer AG
  • AcelRx Pharmaceuticals

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY TYPE OF PAIN- MARKET ANALYSIS, 2019 - 2032

  • Acute Pain
  • Chronic Pain
  • Cancer Pain
  • Neuropathic Pain
  • Postoperative Pain

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Opioids
  • Non-Opioid Analgesics
  • Adjuvant Analgesics
  • Topical Analgesics
  • Others

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY ADMINISTRATION ROUTE- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable
  • Transdermal
  • Topical

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Ambulatory Surgical Centers
  • Home Care Settings
  • Others

GLOBAL PAIN MANAGEMENT THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pain Management Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pain Management Therapeutics Market Snippet by Type of Pain
    • 2.1.2. Pain Management Therapeutics Market Snippet by Drug Class
    • 2.1.3. Pain Management Therapeutics Market Snippet by Administration Route
    • 2.1.4. Pain Management Therapeutics Market Snippet by End-user
    • 2.1.5. Pain Management Therapeutics Market Snippet by Country
    • 2.1.6. Pain Management Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Pain Management Therapeutics Key Market Trends

  • 3.1. Pain Management Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pain Management Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pain Management Therapeutics Market Opportunities
  • 3.4. Pain Management Therapeutics Market Future Trends

4. Pain Management Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pain Management Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pain Management Therapeutics Market Landscape

  • 6.1. Pain Management Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pain Management Therapeutics Market - By Type of Pain

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Pain, 2024 & 2032 (%)
    • 7.1.2. Acute Pain
    • 7.1.3. Chronic Pain
    • 7.1.4. Cancer Pain
    • 7.1.5. Neuropathic Pain
    • 7.1.6. Postoperative Pain

8. Pain Management Therapeutics Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Opioids
    • 8.1.3. Non-Opioid Analgesics
    • 8.1.4. Adjuvant Analgesics
    • 8.1.5. Topical Analgesics
    • 8.1.6. Others

9. Pain Management Therapeutics Market - By Administration Route

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Administration Route, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Injectable
    • 9.1.4. Transdermal
    • 9.1.5. Topical

10. Pain Management Therapeutics Market - By End-user

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Ambulatory Surgical Centers
    • 10.1.4. Home Care Settings
    • 10.1.5. Others

11. Pain Management Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Pain Management Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.8. The U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Pain Management Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Pain Management Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Pain Management Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Pain Management Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type of Pain, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Administration Route, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Pain Management Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Johnson & Johnson
    • 12.2.2. Pfizer Inc.
    • 12.2.3. AbbVie Inc.
    • 12.2.4. Teva Pharmaceutical Industries Ltd.
    • 12.2.5. Eli Lilly and Company
    • 12.2.6. Novartis AG
    • 12.2.7. Grunenthal GmbH
    • 12.2.8. Mylan N.V.
    • 12.2.9. Mallinckrodt Pharmaceuticals
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Allergan (AbbVie)
    • 12.2.12. AstraZeneca plc
    • 12.2.13. Endo International plc
    • 12.2.14. Bristol-Myers Squibb
    • 12.2.15. Bayer AG
    • 12.2.16. AcelRx Pharmaceuticals

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us